Extended Data Fig. 8: Maraviroc transiently inhibits CCR5-dependent moDC migration.
From: Chemokine-defined macrophage niches establish spatial organization of tumor immunity
(a) Experimental design, WT mice were treated intraperitoneal with 500 μg of a CCR5 antagonist, maraviroc, 3, 24, or 48 hours prior to intranasal delivery of 5 μg OVA-Alexa Fluor 488 and 50 μg poly(I:C). Twenty-four hours after antigen intranasal delivery, the lung-draining lymph nodes were harvested, (b) Live cells were first plotted as CD11c versus CD11b, gated CD11c + CD11b+ myeloid cells (left plots) were then plotted as Ly6C versus Alexa Fluor 488 to gate on fluorescently labeled migratory antigen-bearing cells in the lung-draining lymph node (middle plots), antigen-bearing cells were then plotted as Ly6C versus CD26 to identify antigen-bearing Ly6C⁺CD26lo moDCs, as well as antigen-bearing Ly6C−CD26⁺ DCs (right plots). Scatter plot analysis of antigen-bearing Ly6C⁺ moDC migration following Maraviroc treatment at different time points, 3, 24, or 48 hours prior to antigen delivery. Two independent experiments were conducted, n = 3 per group. Data represented as mean ± s.e.m. Statistical significance was determined via one-way ANOVA followed by Bonferroni’s multiple comparison with p < 0.0001. ****p < 0.0001, ns=nonsignificant.
